Advertisement
Advertisement
PRLD
Prelude Therapeutics Incorporated
4.86
USDSponsored
-0.29
-5.63%
May 08, 15:59 UTC -4
Closed
Pre-Market
4.89
+0.03
+0.62%
PRLD Earnings Reports
Positive Surprise Ratio
PRLD beat 15 of 22 last estimates.
68%
Next Report
Tomorrow
Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.24
Implied change from Q4 25 (Revenue/ EPS)
-100.00%
/+20.00%
Implied change from Q1 25 (Revenue/ EPS)
--
/-42.86%
Prelude Therapeutics Incorporated earnings per share and revenue
On Mar 10, 2026, PRLD reported earnings of -0.20 USD per share (EPS) for Q4 25, missing the estimate of -0.02 USD, resulting in a -575.68% surprise. Revenue reached 5.64 million, compared to an expected 35.70 million, with a -84.20% difference. The market reacted with a +16.50% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.24 USD, with revenue projected to reach -- USD, implying an increase of 20.00% EPS, and decrease of -100.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were Prelude Therapeutics Incorporated's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Prelude Therapeutics Incorporated reported EPS of -$0.20, missing estimates by -575.68%, and revenue of $5.64M, -84.2% below expectations.
How did the market react to Prelude Therapeutics Incorporated's Q4 2025 earnings?
The stock price moved up 16.5%, changed from $3.09 before the earnings release to $3.60 the day after.
When is Prelude Therapeutics Incorporated expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Prelude Therapeutics Incorporated's next earnings report?
Based on --
analysts, Prelude Therapeutics Incorporated is expected to report EPS of -$0.24 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement